# Sustained Release Oral Formulation For Treatment Of Parkinsons Disease

> **NCT07709741** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Minnesota** · enrollment: 32 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Formulation A
- **DRUG:** Formulation B
- **DRUG:** Formulation C

## Key facts

- **NCT ID:** NCT07709741
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-04-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709741, "Sustained Release Oral Formulation For Treatment Of Parkinsons Disease". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07709741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*